Clinical and radiological findings of glioblastomas harboring a BRAF V600E mutation

Ishi, Yukitomo; Yamaguchi, Shigeru; Okamoto, Michinari; Sawaya, Ryosuke; Endo, Shogo; Motegi, Hiroaki; Terasaka, Shunsuke; Tanei, Zen-ichi; Hatanaka, Kanako C.; Tanaka, Shinya; Fujimura, Miki

Clinical and radiological findings of glioblastomas harboring a BRAF V600E mutation

Ishi, Yukitomo; Yamaguchi, Shigeru; Okamoto, Michinari et al.

Brain Tumor Pathology, 2022, 39(3), 162-170

Permalink : https://hdl.handle.net/2115/90105

このアイテムのアクセス数:430件（2026-08-13 22:01 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数
BTP 39(3) 162-170	pdf	974 KB	414
Supplementary Figure	pptx	480 KB	140
Supplementary_Material_final	docx	34.2 KB	97

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/90105
タイトル	Clinical and radiological findings of glioblastomas harboring a BRAF V600E mutation
著者	Ishi, Yukitomo ; Yamaguchi, Shigeru ; Okamoto, Michinari ; Sawaya, Ryosuke ; Endo, Shogo ; Motegi, Hiroaki ; Terasaka, Shunsuke ; Tanei, Zen-ichi ; Hatanaka, Kanako C. ; Tanaka, Shinya ; Fujimura, Miki
e-Rad_Researcher 30812284 著者名 Ishi, Yukitomo
著者名 Yamaguchi, Shigeru
著者名 Okamoto, Michinari
著者名 Sawaya, Ryosuke
著者名 Endo, Shogo
著者名 Motegi, Hiroaki
著者名 Terasaka, Shunsuke
著者名 Tanei, Zen-ichi
著者名 Hatanaka, Kanako C.
e-Rad_Researcher 70261287 著者名 Tanaka, Shinya
e-Rad_Researcher 00361098 著者名 Fujimura, Miki
言語	英語
キーワード	BRAF V600E
	Glioblastoma
	IDH1
	2
	MRI
発行日	2022-07-01
出版者	Springer
収録物名	Brain Tumor Pathology
巻(号)	39(3)
ページ	162-170
抄録	The aim of this study was to analyze the clinical and radiological characteristics of glioblastomas (GBMs) harboring a BRAF mutation. Sequencing analysis of BRAF, IDH1/2, and TERT promoters was performed on GBM samples of patients older than 15 years. The clinical, pathological, and radiological data of patients were retrospectively reviewed. Patients were classified into three groups according to their BRAF and IDH1/2 status: BRAF group, IDH group, and BRAF/IDH-wild-type (WT) group. Among 179 GBM cases, we identified nine cases with a BRAF mutation and nine with IDH mutation. The WT group had 161 cases. Age at onset in the BRAF group was significantly lower compared to the WT group and was similar to the IDH group. In cases with negative IDH1-R132H staining and age < 55 years, 15.2% were BRAF-mutant cases. Similar to the IDH group, overall survival of the BRAF group was significantly longer compared with the WT group. Among nine cases in the BRAF group, three cases had hemorrhagic onset and prior lesions were observed in two cases. In conclusion, age < 55 years, being IDH1-R132H negative, with hemorrhagic onset or the presence of prior lesions are factors that signal recommendation of BRAF analysis for adult GBM patients.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1007/s10014-022-00432-7
PISSN	1433-7398
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1007/s10014-022-00432-7